Skip to content
ClinCalc Pro
Menu
H1 antihistamine + mast cell stabiliser

Ketotifen

Brand names: Zaditen

Ketotifen is an antihistamine with mast cell stabilising properties used as eye drops for the treatment of seasonal allergic conjunctivitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It blocks histamine H1 receptors and stabilises mast cells to reduce the release of inflammatory mediators, relieving the itching, redness and watering of allergic conjunctivitis.

Prescribing in practice

  • Preservatives such as benzalkonium chloride in some formulations can be absorbed by soft contact lenses and cause ocular irritation, so lenses should be removed before instillation and reinserted only after a suitable interval.
  • Transient stinging or burning and, rarely, mild drowsiness may occur.
  • Used for symptomatic relief of allergic conjunctivitis and is generally well tolerated for seasonal use.

Monitoring

No systemic monitoring is required; review symptom control clinically and reassess if symptoms persist or worsen.

Counselling the patient

  • Remove soft contact lenses before instilling and wait the recommended interval before reinserting them.
  • Brief blurring or stinging may occur after instillation, so wait until vision clears before driving.

Evidence & guidelines

Topical antihistamine and mast cell stabilising drops are recommended for allergic conjunctivitis in NICE Clinical Knowledge Summaries.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.